340 results match your criteria: "The Alfred and Monash University[Affiliation]"
PLoS One
December 2024
Disease Elimination, Burnet Institute, Melbourne, VIC, Australia.
Objectives: Whilst public health measures were effective in reducing COVID-19 transmission, unintended negative consequences may have occurred. This study aims to assess changes alcohol consumption and the heavy episodic drinking (HED) during the pandemic.
Methods: Data were from the Optimise Study, a longitudinal cohort of Australian adults September 2020-August 2022 that over-sampled priority populations at higher risk of contracting COVID-19, developing severe COVID-19 or experiencing adverse consequences of lockdowns.
Clin Infect Dis
September 2024
Department of Gastroenterology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
Cancers (Basel)
August 2024
Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
Background & Aims: Hepatocellular carcinoma (HCC) presents a significant global health challenge, particularly among individuals with liver cirrhosis, with hepatitis C (HCV) a major cause. In people with HCV-related cirrhosis, an increased risk of HCC remains after cure. HCC surveillance with six monthly ultrasounds has been shown to improve survival.
View Article and Find Full Text PDFInt J Health Policy Manag
August 2024
Centre for Health Communication and Participation, School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia.
Background: Community engagement is key to developing local and context-specific strategies for the prevention and control of COVID-19. However, expedited research design and approval in the early days of the pandemic may have limited the opportunities for community members to influence pandemic-related research. In this study, we sought to understand how a Community Engagement Group (CEG) could impact a large longitudinal COVID-19 research project (Optimise), when involved solely in the interpretation and knowledge translation phases of the research.
View Article and Find Full Text PDFLancet Reg Health West Pac
July 2024
Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia.
Med Mycol
June 2024
Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia.
Med Mycol
June 2024
Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia.
The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list. This systematic review aimed to evaluate the epidemiology and impact of eumycetoma. PubMed and Web of Science were searched to identify studies published between 1 January 2011 and 19 February 2021.
View Article and Find Full Text PDFFront Public Health
June 2024
Burnet Institute, Melbourne, VIC, Australia.
Introduction: A disproportionate number of COVID-19 deaths occur in Residential Aged Care Facilities (RACFs), where better evidence is needed to target COVID-19 interventions to prevent mortality. This study used an agent-based model to assess the role of community prevalence, vaccination strategies, and non-pharmaceutical interventions (NPIs) on COVID-19 outcomes in RACFs in Victoria, Australia.
Methods: The model simulated outbreaks in RACFs over time, and was calibrated to distributions for outbreak size, outbreak duration, and case fatality rate in Victorian RACFs over 2022.
Hepatology
May 2024
Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Australia.
Background And Aims: No direct-acting antiviral is currently approved for acute HCV infection, delaying treatment. We investigated the effectiveness and safety of 8-week glecaprevir/pibrentasvir (G/P) in patients with acute HCV infection.
Approach And Results: This noninterventional, single-arm, retrospective chart review was designed to enroll adults/adolescents with acute HCV infection.
Front Immunol
March 2024
Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.
Background: Hepatitis C virus (HCV) infections are more prevalent in people who inject drugs (PWID) who often experience additional health risks. HCV induces inflammation and immune alterations that contribute to hepatic and non-hepatic morbidities. It remains unclear whether curative direct acting antiviral (DAA) therapy completely reverses immune alterations in PWID.
View Article and Find Full Text PDFANZ J Surg
June 2024
Department of Medicine, Royal Melbourne Hospital and The University of Melbourne, Parkville, Victoria, Australia.
Int J Drug Policy
March 2024
Department of Gastroenterology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; Faculty of Medicine, University of Melbourne, Parkville, Victoria, Australia. Electronic address:
Background: To achieve hepatitis C virus (HCV) elimination targets, simplified care engaging people who inject drugs is required. We evaluated whether fingerstick HCV RNA point-of-care testing (PoCT) increased the proportion of clients attending a supervised injecting facility who were tested for hepatitis C.
Methods: Prospective single-arm study with recruitment between 9 November 2020 and 28 January 2021 and follow-up to 31 July 2021.
Int J Drug Policy
February 2024
Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health, iPLESP, Paris, France; AP-HP, Department of Infectious Diseases, Saint-Antoine Hospital, Paris, France.
Background: Among people living with HIV and hepatitis C virus (HCV), people who inject drugs (PWID) have historically experienced higher mortality rates. Direct-acting antivirals (DAA), which have led to a 90 % HCV cure rate independently of HIV co-infection, have improved mortality rates. However, DAA era mortality trends among PWID with HIV/HCV remain unknown.
View Article and Find Full Text PDFEClinicalMedicine
December 2023
Royal Papworth Hospital Biomedical Campus, Cambridge, CB2 0AY, UK.
Heart failure imposes a significant burden on all health care systems and has a 5-year mortality of 50%. Heart transplantation and ventricular assist device (VAD) implantation are the definitive therapies for end stage heart disease, although transplantation appears to offer superior long-term survival and quality of life over VAD implantation. Transplantation is limited by a shortage in donor hearts, resulting in considerable waiting list mortality.
View Article and Find Full Text PDFBiofilm
December 2023
Wenzhou Medical University-Monash BDI Alliance in Clinical and Experimental Biomedicine, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, 325000, China.
Background: Recurrent vulvovaginal candidiasis (RVVC) is a recalcitrant medical condition that affects many women of reproductive age. The importance of biofilm formation by in RVVC has been recently questioned. This study aimed to elucidate the fundamental growth modes of in the vagina of patients with RVVC or sporadic vulvovaginal candidiasis (VVC) and to assess their roles in the persistence of RVVC.
View Article and Find Full Text PDFNat Rev Gastroenterol Hepatol
January 2024
Disease Elimination, Burnet Institute, Melbourne, Victoria, Australia.
J Virus Erad
September 2023
Victorian Infectious Diseases Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria, 3000, Australia.
Introduction: Antiretroviral therapy for people living with HIV-1 must be taken lifelong due to the persistence of latent virus in long-lived and proliferating CD4 T cells. Vitamin D is a steroidal gene transcription regulator which exerts diverse effects on immune and epithelial cells including reductions in CD4 T cell proliferation and improvement in gut barrier integrity. We hypothesised that a high dose of vitamin D would reduce the size of the HIV-1 reservoir by reducing CD4 T cell proliferation.
View Article and Find Full Text PDFEpilepsy Res
October 2023
Melbourne School of Psychological Sciences, University of Melbourne, Victoria, Australia; The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia; Comprehensive Epilepsy Program, Austin Health, University of Melbourne, Victoria, Australia; Department of Clinical Neuropsychology, Austin Health, Heidelberg, Victoria, Australia.
Open Forum Infect Dis
August 2023
Burnet Institute, Melbourne, Australia.
BMJ Open
July 2023
Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Objectives: Direct-acting antivirals provide an opportunity to eliminate hepatitis C virus (HCV) as a public health threat in Australia, yet barriers to care remain. In this study, we use baseline data from a longitudinal cohort of people who inject drugs to understand differences in participant characteristics and explore experiences of stigma, health service utilisation and health literacy between three care cascade groups.
Design: Cross-sectional.
Front Public Health
June 2023
Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.
Background: In 2021, the Australian Government Department of Health commissioned a consortium of modelling groups to generate evidence assisting the transition from a goal of no community COVID-19 transmission to 'living with COVID-19', with adverse health and social consequences limited by vaccination and other measures. Due to the extended school closures over 2020-21, maximizing face-to-face teaching was a major objective during this transition. The consortium was tasked with informing school surveillance and contact management strategies to minimize infections and support this goal.
View Article and Find Full Text PDFEpidemics
September 2023
Disease Elimination Program, Burnet Institute, Melbourne, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Background: Prior to mid-2021, Australia's approach to COVID-19 was to eliminate community transmission. However, between August-November 2021, the state of Victoria, Australia, experienced an outbreak of the Delta variant that continued to grow despite extensive lockdowns and public health measures in place. While these public health restrictions were ultimately unable to stop community transmission, they likely had a major impact reducing transmission and adverse health outcomes relative to voluntary risk-mitigation only (e.
View Article and Find Full Text PDFAm J Respir Crit Care Med
September 2023
Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
BMC Public Health
May 2023
Disease Elimination Program, Burnet Institute, 85 Commercial Rd, Melbourne, Victoria, Australia.
Background: Policy responses to COVID-19 in Victoria, Australia over 2020-2021 have been supported by evidence generated through mathematical modelling. This study describes the design, key findings, and process for policy translation of a series of modelling studies conducted for the Victorian Department of Health COVID-19 response team during this period.
Methods: An agent-based model, Covasim, was used to simulate the impact of policy interventions on COVID-19 outbreaks and epidemic waves.
Biofilm
December 2023
Infection Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, 3800, Australia.
Objectives: Driveline infections are a major complication of ventricular assist device (VAD) therapy. A newly introduced Carbothane driveline has preliminarily demonstrated anti-infective potential against driveline infections. This study aimed to comprehensively assess the anti-biofilm capability of the Carbothane driveline and explore its physicochemical characteristics.
View Article and Find Full Text PDF